JG26 attenuates ADAM17 metalloproteinase-mediated ACE2 receptor processing and SARS-CoV-2 infection in vitro.

Valentina GentiliSilvia BeltramiDoretta CuffaroGiorgia CianciGloria MainiRoberta RizzoMarco MacchiaArmando RosselloDaria BortolottiElisa Nuti

Published in: Pharmacological reports : PR (2024)

JG26, an ADAM17 inhibitor, demonstrated promising antiviral activity against SARS-CoV-2 infection, likely attributed to reduced sACE2 availability, thus limiting viral dissemination.

Keyphrases

respiratory syndrome coronavirus
sars cov
coronavirus disease